Shuttle Pharmaceuticals Holdings, Inc.

SHPH

$3.58

+$0.18 (5.29%)

Closed

10-for-1 reverse stock split effective today triggers 21% drop in SHPH

Loading chart...

IndexN/A

Market Cap0.00B

Enterprise Value0.00B

Income$-0.00B

Sales$0.00B

EmployeesN/A

P/E-0.17

P/SN/A

P/B1.31

P/C-0.31

EV/EBITDA-0.25

EV/SalesN/A

EPS (ttm)-21.54

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume0.19M

Shs Outstand0.00B

Change5.29%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Jun 2608:00AMUnited Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site(newsfilecorp.com)

Jun 2504:05PMUnited Dogecoin Advances Data Centre and Power Infrastructure Strategy to Support DOGE Mining and AI Hosting(newsfilecorp.com)

Jun 908:30AMShuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time(newsfilecorp.com)

May 1404:05PMShuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs

Insider Trading

View All

Insider

Type

Price

Value

Date

HRT FINANCIAL LP

Buy

6.8K

$3.23

$22K

Jun 30, 26

Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.

CEO: Christopher Robert CooperEmployees: 9www.shuttlepharma.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2018	FY 2017
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	$5.97K	$60.83K	$54.95K	$18.00K	$18.74K
Gross Profit	N/A	N/A	$-5.97K	$-60.83K	$-54.95K	$-18.00K	$-18.74K
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$7.70M	$5.89M	$2.34M	$1.68M	$454.57K	$568.63K	$185.15K
Operating Income	$-7.70M	$-5.89M	$-2.34M	$-1.74M	$-509.52K	$-586.63K	$-203.89K
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-9.14M	$-6.59M	$-5.00M	$-1.15M	$-805.73K	$-626.14K	$-213.59K
Net Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-885.73	$-0.41	$-0.30	$-0.09	$-0.07	$-0.05	$-0.02
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Shuttle Pharmaceuticals Holdings, Inc.

Insider Trading

Discover more